alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
IV 

109TH CONGRESS 

2D SESSION H. RES. 652 

Expressing the sense of the House of Representatives that there should 

be established a National Inflammatory Skin Disease Awareness Month. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 31, 2006 

Mrs. JO ANN DAVIS of Virginia submitted the following resolution; which was 

referred to the Committee on Government Reform 

RESOLUTION 

Expressing the sense of the House of Representatives that 

there should be established a National Inflammatory 

Skin Disease Awareness Month. 

Whereas inflammatory skin diseases affect men, women, and 

children of all ages and races; 

Whereas these diseases can be very distressing to those who 

have them, causing great discomfort and emotional 

stress; 

Whereas inflammatory skin diseases include a wide range of 

symptoms and a broad category of skin conditions, including eczema, acne, poison ivy, contact dermatitis, and 

psoriasis, among others; 

Whereas inflammatory skin disease affects citizens across the 

United States; 
2 

•HRES 652 IH 

Whereas it is essential to educate the public on the symptoms, treatments, and cures related to inflammatory skin 

diseases; and 

Whereas December would be an appropriate month to establish as National Inflammatory Skin Disease Awareness 

Month: Now, therefore, be it 

1 Resolved, That it is the sense of the House of Rep2 resentatives that there should be established a National 

3 Inflammatory Skin Disease Awareness Month. 

Æ
Exhibit 31.1
 CERTIFICATION
      (a)
    
    Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in which
this report is being prepared;(b)
    
    Designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;(c)
    
    Evaluated the effectiveness of the registrants disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report
based on such evaluation; and(d)
    
    Disclosed in this report any change in the registrants internal control over
financial reporting that occurred during the registrants most recent fiscal quarter
(the registrants fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrants
internal control over financial reporting; and
  (a)
    
    All significant deficiencies and material weaknesses in the design or operation
of internal control over financial reporting which are reasonably likely to adversely
affect the registrants ability to record, process, summarize and report financial
information; and(b)
    
    Any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrants internal control over financial
reporting.
  /s/ Nathan ZommerNathan Zommer, Chairman of the Boardand Chief Executive Officer
Editorial Note on Part 316
Editorial Note: Nomenclature changes to part 316 appear at 69 FR 13717, Mar. 24, 2004.

§ 316.36 Insufficient quantities of orphan drugs. ( a ) Under section 527 of the act, whenever the Director has reason to believe that the holder of exclusive approval cannot assure the availability of sufficient quantities of an orphan drug to meet the needs of patients with the disease or condition for which the drug was designated, the Director will so notify the holder of this possible insufficiency and will offer the holder one of the following options, which must be exercised by a time that the Director specifies: ( 1 ) Provide the Director in writing, or orally, or both, at the Director's discretion, views and data as to how the holder can assure the availability of sufficient quantities of the orphan drug within a reasonable time to meet the needs of patients with the disease or condition for which the drug was designated; or
( 2 ) Provide the Director in writing the holder's consent for the approval of other marketing applications for the same drug before the expiration of the 7-year period of exclusive approval.
( b ) If, within the time that the Director specifies, the holder fails to consent to the approval of other marketing applications and if the Director finds that the holder has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated, the Director will issue a written order withdrawing the drug product's exclusive approval. This order will embody the Director's findings and conclusions and will constitute final agency action. An order withdrawing the sponsor's exclusive marketing rights may issue whether or not there are other sponsors that can assure the availability of alternative sources of supply. Once withdrawn under this section, exclusive approval may not be reinstated for that drug.
<PAGE>   1
                                                                      EXHIBIT 23
                                                                      ----------

                       CONSENT OF INDEPENDENT ACCOUNTANTS

We consent to the incorporation by reference in the registration statements of
Intimate Brands, Inc. on Form S-8, Registration Nos. 333-1960, 333-04921,
333-04923 and 333-10215 of our report dated February 17, 1999, on our audits of
the consolidated financial statements of Intimate Brands, Inc. and Subsidiaries
as of January 30, 1999, and January 31, 1998, and for the fiscal years ended
January 30, 1999, January 31, 1998 and February 1, 1997, which report is
incorporated by reference in this Annual Report on Form 10-K.


PricewaterhouseCoopers LLP

Columbus, Ohio
April 26, 1999
EXHIBIT
32.2





CERTIFICATION
OF CHIEF FINANCIAL OFFICER





Pursuant
to Section 906 of the Sarbanes Oxley Act of 2002 (18 U.S.C. 1350)
and


Rules
13a-14(b) of the Securities Exchange Act of 1934




I,
Dominick Ragone, Chief Financial Officer of Icahn Enterprises G.P. Inc., the
general partner of Icahn Enterprises L.P. (the “Registrant”), certify that, to
the best of my knowledge, based upon a review of the Icahn Enterprises L.P.
quarterly report on Form 10-Q for the period ended June 30, 2009 of the
Registrant (the “Report”):




(1) The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended; and




(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Registrant.




/s/
      Dominick RagoneDominick
      RagoneChief
      Financial Officer of Icahn Enterprises G.P. Inc., the general partner of
      Icahn Enterprises L.P.





Date:
August 5, 2009
§ 20.108 Agreements between the Food and Drug Administration and other departments, agencies, and organizations. ( a ) All written agreements and understandings signed by the Food and Drug Administration and other departments, agencies, and organizations are available for public disclosure.
( b ) All written agreements and memoranda of understanding between FDA and any entity, including, but not limited to other departments, Agencies, and organizations will be made available through the Food and Drug Administration Web site at *http://www.fda.gov* once finalized.
( c ) Agreements and understandings signed by officials of FDA with respect to activities of the Office of Criminal Investigations are exempt from the requirements set forth in paragraph (b) of this section. Although such agreements and understandings will not be made available through the FDA Web site, these agreements will be available for disclosure in response to a request from the public after deletion of information that would disclose confidential investigative techniques or procedures, or information that would disclose guidelines for law enforcement investigations if such disclosure could reasonably be expected to risk circumvention of the law.
[42 FR 15616, Mar. 22, 1977, as amended at 46 FR 8457, Jan. 27, 1981; 58 FR 48794, 48796, Sept. 20, 1993; 76 FR 31470, June 1, 2011; 77 FR 50591, Aug. 22, 2012]
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.71 Magnesium labeling. ( a ) The labeling of over-the-counter (OTC) drug products intended for oral ingestion shall contain the magnesium content per dosage unit (e.g., tablet, teaspoonful) if the magnesium content of a single maximum recommended dose of the product (which may be one or more dosage units) is 8 milligrams or more. OTC drug products intended for oral ingestion include gum and lozenge dosage forms, but do not include dentifrices, mouthwashes, or mouth rinses.
( b ) The magnesium content shall be expressed in milligrams or grams per dosage unit and shall include the total amount of magnesium regardless of the source, i.e., from both active and inactive ingredients. If the dosage unit contains less than 1 gram of magnesium, milligrams should be used. The magnesium content shall be rounded-off to the nearest 5 milligrams (or nearest tenth of a gram if over 1 gram). The magnesium content per dosage unit shall follow the heading “Other information” as stated in § 201.66(c)(7).
( c ) The labeling of OTC drug products intended for oral ingestion shall contain the following statement under the heading “Warning” (or “Warnings” if it appears with additional warning statements) if the amount of magnesium present in the labeled maximum daily dose of the product is more than 600 milligrams: “Ask a doctor before use if you have [in bold type] [bullet][1] kidney disease [bullet] a magnesium-restricted diet”. The warnings in §§ 201.64(c), 201.70(c), 201.71(c), and 201.72(c) may be combined, if applicable, provided the ingredients are listed in alphabetical order, e.g., a magnesium or potassium-restricted diet.
( d ) Any product subject to this paragraph that is not labeled as required by this paragraph and that is initially introduced or initially delivered for introduction into interstate commerce after the following dates is misbranded under sections 201(n) and 502(a) and (f) of the Federal Food, Drug, and Cosmetic Act. ( 1 ) As of the date of approval of the application for any single entity and combination products subject to drug marketing applications approved on or after April 23, 2004.
( 2 ) September 24. 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject of any OTC drug monograph, or subject to drug marketing applications approved before April 23, 2004.
[69 FR 13734, Mar. 24, 2004] Footnotes -
201.71
[1] See § 201.66(b)(4) of this chapter for definition of bullet symbol.
# L_2018249EN.01000101.xml

| 4.10.2018 | EN | Official Journal of the European Union | L 249/1 |
| --- | --- | --- | --- |

4.10.2018

EN

Official Journal of the European Union

L 249/1

---

COMMISSION IMPLEMENTING REGULATION (EU) 2018/1476

of 3 October 2018

amending Council Regulation (EC) No 1210/2003 concerning certain specific restrictions on economic and financial relations with Iraq

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Council Regulation (EC) No 1210/2003 of 7 July 2003 concerning certain specific restrictions on economic and financial relations with Iraq and repealing Regulation (EC) No 2465/96 (1), and in particular Article 11(b) thereof,

Whereas:

| (1) | Annex III to Regulation (EC) No 1210/2003 lists public bodies, corporations and agencies and natural and legal persons, bodies and entities of the previous government of Iraq covered by the freezing of funds and economic resources that were located outside Iraq on the date of 22 May 2003 under that Regulation. |
| --- | --- |

(1)

Annex III to Regulation (EC) No 1210/2003 lists public bodies, corporations and agencies and natural and legal persons, bodies and entities of the previous government of Iraq covered by the freezing of funds and economic resources that were located outside Iraq on the date of 22 May 2003 under that Regulation.

| (2) | On 28 September 2018, the Sanctions Committee of the United Nations Security Council decided to remove one entry from the list of persons or entities to whom the freezing of funds and economic resources should apply. |
| --- | --- |

(2)

On 28 September 2018, the Sanctions Committee of the United Nations Security Council decided to remove one entry from the list of persons or entities to whom the freezing of funds and economic resources should apply.

| (3) | Annex III to Regulation (EC) No 1210/2003 should therefore be amended accordingly, |
| --- | --- |

(3)

Annex III to Regulation (EC) No 1210/2003 should therefore be amended accordingly,

HAS ADOPTED THIS REGULATION:

Article 1

Annex III to Regulation (EC) No 1210/2003 is amended as set out in the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the day following that of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 3 October 2018.

For the Commission,

On behalf of the President,

Head of the Service for Foreign Policy Instruments

---

(1)  
  OJ L 169, 8.7.2003, p. 6.

1

---

ANNEX

In Annex III to Council Regulation (EC) No 1210/2003, the following entry is deleted:

| ‘128. | STATE ENTERPRISE FOR AUTOMOTIVE INDUSTRY (alias STATE ENTERPRISE FOR AUTOMOTIVE INDUSTRIES). Address: P.O. Box 138, Iskandariya-Babylon, Iraq.’ |
| --- | --- |

‘128.

---
# L_2018152EN.01006001.xml

| 15.6.2018 | EN | Official Journal of the European Union | L 152/60 |
| --- | --- | --- | --- |

15.6.2018

EN

Official Journal of the European Union

L 152/60

---

Corrigendum to Council Implementing Regulation (EU) 2018/705 of 14 May 2018 implementing Regulation (EU) No 269/2014 concerning restrictive measures in respect of actions undermining or threatening the territorial integrity, sovereignty and independence of Ukraine

(
  Official Journal of the European Union L 118 I of 14 May 2018
  )

On page 2, in the Annex, in the column ‘Identifying information’, for entries 162 and 163, the addresses are deleted.

---
<PAGE>   1
                                                               Exhibit 5.1  
                 


             [GRAHAM & JAMES LLP/RIDDELL WILLIAMS P.S. LETTERHEAD]



August 4, 1997

Innova Corporation
Gateway North, Building 2
3325 South 116th Street
Seattle, WA 98168-1974

RE:  2,875,000 SHARES OF COMMON STOCK OF INNOVA CORPORATION

Ladies and Gentlemen:

This opinion is furnished in connection with a Registration Statement on Form
S-1 (Registration No. 333-29547), as amended (the "Registration Statement"), of
Innova Corporation, a Washington corporation (the "Company"), under which
2,500,000 shares of Common Stock of the Company (the "Common Stock"), together
with up to an additional 375,000 shares of Common Stock to cover
over-allotments, are being registered by the Company for sale under the
Securities Act of 1933, as amended (all of such shares will be referred to as
the "Shares").

As counsel for the Company, we are familiar with the Company's Restated Articles
of Incorporation, as amended, the Company's Amended and Restated Bylaws, as
amended, and the records of the corporate proceedings of the Company, and we
have assisted in the preparation of the Registration Statement, including the
Prospectus contained therein.

Based on the foregoing, we are of the opinion that, when (a) the Registration
Statement shall have been declared effective by order of the Securities and
Exchange Commission, (b) the Shares shall have been offered and sold in the
manner referred to in the Registration Statement, (c) certificates for the
Shares shall have been duly issued by the Company and registered by its
registrar, and (d) the Company shall have received the consideration required
for the Shares as contemplated by the Registration Statement, the Shares will be
validly issued, fully paid and nonassessable.


<PAGE>   2
Innova Corporation
August 4, 1997
Page 2


We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement and to the inclusion in the Prospectus contained therein
of the reference to our firm under the heading "Legal Matters." In giving such
consent, we do not admit that we are in the category of the persons whose
consent is required under Section 7 of the Securities Act of 1933, as amended.

Very truly yours,


/s/ BENJAMIN F. STEPHENS
Benjamin F. Stephens
       of
Graham & James LLP/Riddell Williams P.S.


BFS:ml
**EXHIBIT 32.1****CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350**     Pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002,I, Gordon Ellis, President and Chief Executive Officer, certify that:1. To my knowledge, this report fully complies with the requirements of Section 13(a) or 15(d) ofthe Securities Exchange Act of 1934; and 2. To my knowledge, the information in this report fairly presents, in all material respects, thefinancial condition and results of operations of International Absorbents Inc. as of July 31, 2005.                                                        /s/  GORDON ELLIS   Gordon Ellis  Date: September 15, 2005 *President and Chief Executive Officer*
----

----

| Name of Subsidiary                                                  |   | Percentage of Ownership |   | Jurisdiction of Incorporation |   |
|---------------------------------------------------------------------|--------|-------------------------|--------|-------------------------------|--------|
| Ellomay Clean Energy Ltd.                                           |   | 100%                    |   | Israel                        |   |
| Ellomay Clean Energy LP                                             |   | 100%                    |   | Israel                        |   |
| Ellomay Luxemburg Holdings S.àr.l.                             |   | 100%                    |   | Luxemburg                     |   |
| Ellomay PV One S.r.l.                                               |   | 100%1                   |   | Italy                         |   |
| Ellomay PV Two S.r.l.                                               |   | 100%1                   |   | Italy                         |   |
| Ellomay PV Five S.r.l.                                              |   | 100%1                   |   | Italy                         |   |
| Ellomay PV Six S.r.l.                                               |   | 100%1                   |   | Italy                         |   |
| Ellomay PV Seven S.r.l. (formerly Energy Resources Galatina S.r.l.) |   | 100%1                   |   | Italy                         |   |
| Pedale S.r.l.                                                       |   | 100%1                   |   | Italy                         |   |
| Luma Solar S.r.l.                                                   |   | 100%1                   |   | Italy                         |   |
| Murgia Solar S.r.l.                                                 |   | 100%1                   |   | Italy                         |   |
| Soleco S.r.l                                                        |   | 100%1                   |   | Italy                         |   |
| Technoenergy S.r.l                                                  |   | 100%1                   |   | Italy                         |   |
| Ellomay Spain S.L.2                                            |   | 85%1                    |   | Spain                         |   |

| 1.   | Held by Ellomay Luxemburg Holdings S.àr.l. |
|----------------|-------------------------------------------------|

| 2.   | Ellomay Spain owns 21 Spanish companies, each holding a 90 kW solar installation portion of the Riconada II, the first named Energía Solar Fotovoltaica Parque 15, S.L. and the others bear a similar name with references to different numbers (16-34 and 69). |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----
<PAGE>   1

FRONTIER FINANCIAL CORPORATION AND SUBSIDIARIES                       EXHIBIT 11
COMPUTATION OF EARNINGS PER SHARE
--------------------------------------------------------------------------------


<TABLE>
<CAPTION>
                                                For Six Months Ended June 30,

                                                   1998              1997
                                                ----------        ----------
<S>                                             <C>               <C>       
Net Income                                      $9,528,090        $8,375,821
                                                ==========        ==========

Computation of average
shares outstanding

             Shares outstanding at
             beginning of year                   7,350,561         6,830,666

             Additional shares deemed
             outstanding because of
             stock dividends                       516,035           991,720

             Additional shares deemed
             outstanding because of
             stock split                                 0                 0

             Shares issued during the
             year times average time
             outstanding during the year            11,471             7,535
                                                ----------        ----------

Average basic shares outstanding                 7,878,067         7,829,921
                                                ----------        ----------

Dilutive shares                                     77,976            77,812
                                                ----------        ----------

Average fully diluted shares outstanding         7,956,043         7,907,733
                                                ----------        ----------

Basic earnings per share                        $     1.21        $     1.07
                                                ==========        ==========


Fully diluted earnings per share                $     1.20        $     1.06
                                                ==========        ==========
</TABLE>
[No. 19974-2-II.

Division Two.

November 21, 1997.]

#### The State of Washington, *Respondent,*v. Cecilio Zamora Velez, *Appellant.*

Appeal from a judgment of the Superior Court for Pierce County, No. 94-1-05294-4, Thomas R. Sauriol, J., entered September 25, 1995. *Affirmed*by unpublished opinion per Bridgewater, J., concurred in by Houghton, C.J., and Armstrong, J.
# L_2018036EN.01003801.xml

| 9.2.2018 | EN | Official Journal of the European Union | L 36/38 |
| --- | --- | --- | --- |

9.2.2018

EN

Official Journal of the European Union

L 36/38

---

Corrigendum to Council Implementing Regulation (EU) 2018/12 of 8 January 2018 implementing Regulation (EU) 2017/1509 concerning restrictive measures against the Democratic People's Republic of Korea

(
  Official Journal of the European Union L 4 of 9 January 2018
  )

On page 3, the Annex, Part (a), entry 75, third column:

for:

‘DOB: 20.8.1965

Passport No 563233049 expires 11.3.2019.

...’,

read:

‘DOB: 21.8.1957

Passport No 563233049 expires 9.5.2018.

...’.

---